ArticleJournal of experimental orthopaedics2025
Blood flow restriction-enhanced platelet-rich plasma: A pilot randomised controlled trial protocol.
Article in Journal of experimental orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood flow restriction training before platelet-rich plasma preparation induces a significant reduction in its interleukin-6 levels: A pilot randomised controlled trial.Journal of experimental orthopaedics · 2025Article
- Blood flow restriction-enhanced platelet-rich plasma: A pilot randomised controlled trial protocol.Journal of experimental orthopaedics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess platelet-rich plasma (PRP) changes in platelet and leucocyte count, insulin-like growth factor 1 (IGF-1), and interleukin 6 (IL-6) concentration after bilateral low-load knee extensions under blood flow restriction (BFR). Methods: The present randomised controlled trial protocol will include two groups: the intervention group, which will undergo bilateral knee extensions under BFR, and the control group, which will perform bilateral knee extensions without BFR. Participants will be randomly allocated in a 1:1 ratio. Twenty-two healthy individuals will be enrolled if the predefined inclusion criteria are met: (1) males, (2) ages 18-40, (3) Tegner activity level ≥5 and (4) with no musculoskeletal conditions that would interfere with exercise. Exclusion criteria include (1) individuals with systemic inflammatory diseases, (2) cardiovascular risk factors, (3) any blood dyscrasia, (4) Tegner Activity scale scores <5, (5) under nonsteroidal anti-inflammatory drugs and aspirin treatment within one week before testing or (6) that had previously performed exercises on the testing day. The participant will perform low-load bilateral knee extensions under BFR following a standard protocol of 30-15-15-15 repetitions of consecutive sets with 30-s rest intervals at 80% of limb occlusive pressure and 30% of 1-RM load. PRP platelet and leucocyte count, IGF-1 and IL-6 concentration measurements (via flow cytometry, chemiluminescence testing and immunochromatography, respectively) will be conducted before exercise and 10, 20 and 30 min after the intervention. Results: The expected outcome is that the standard protocol of low-load bilateral knee extensions under BFR will increase the platelet and leucocyte count, IGF-1 and IL-6 in the PRP preparation. Conclusion: The current protocol allows the study of an enhanced PRP formulation for its potential implementation in multiple sports injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.